Recurrent endometrial carcinoma: prognosis for patients with recurrence within 6 to 12 months is worse relative to those relapsing at 12 months or later

详细信息    查看全文

• 作者：Takahito Miyake ; Yutaka Ueda ; Tomomi Egawa-Takata ; Shinya Matsuzaki ; Takuhei Yokoyama ; Yukari Miyoshi ; Toshihiro Kimura ; Kiyoshi Yoshino ; Masami Fujita ; Masato Yamasaki ; Takayuki Enomoto ; Tadashi Kimura
• 关键词：chemotherapy ; endometrial cancer ; partially sensitive ; prognosis ; treatment-free interval
• 刊名：American Journal of Obstetrics and Gynecology
• 出版年：2011
• 出版时间：June 2011
• 年：2011
• 卷：204
• 期：6
• 页码：535.e1-535.e5
• 全文大小：265 K

文摘

Objective

We evaluated association of prognosis of endometrial carcinoma patients and treatment-free intervals (TFIs).

Study Design

We compared the effectiveness of second-line chemotherapy performed for patients with TFIs of 6-12 months and 12 or more months following a first-line chemotherapy based on taxane (paclitaxel) and carboplatin, with or without the anthracycline (TC).

Results

Progression-free and overall survivals were significantly shorter in patients with TFIs of 6-12 months than those with TFIs of 12 or more months. Among the patients who received similar second-line chemotherapy, response rates of 15 patients with TFIs of 12 or more months and 7 patients with TFIs of 6-12 months were 67 % and 43 % , respectively. Progression-free survival was significantly worse in those with TFIs of 6-12 months (median, 7 months) than those with TFIs of 12 or more months (median, 12 months).

Conclusion

Our small retrospective analysis suggests that recurrent endometrial carcinomas with TFIs of 6-12 months can be regarded as being partially sensitive to TC-based chemotherapy.